Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

BACKGROUND: FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic colorectal cancer (mCRC) unselected for biomolecular alterations. Generally, tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Damato, Angela, Iachetta, Francesco, Antonuzzo, Lorenzo, Nasti, Guglielmo, Bergamo, Francesca, Bordonaro, Roberto, Maiello, Evaristo, Zaniboni, Alberto, Tonini, Giuseppe, Romagnani, Alessandra, Berselli, Annalisa, Normanno, Nicola, Pinto, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457535/
https://www.ncbi.nlm.nih.gov/pubmed/32867715
http://dx.doi.org/10.1186/s12885-020-07268-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457535/
https://www.ncbi.nlm.nih.gov/pubmed/32867715
http://dx.doi.org/10.1186/s12885-020-07268-4

Ejemplares similares